<SEC-DOCUMENT>0001279569-20-000787.txt : 20200515
<SEC-HEADER>0001279569-20-000787.hdr.sgml : 20200515
<ACCEPTANCE-DATETIME>20200515083437
ACCESSION NUMBER:		0001279569-20-000787
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200515
FILED AS OF DATE:		20200515
DATE AS OF CHANGE:		20200515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		20880786

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of May
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><B>EXHIBITS
INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 12%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 12pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 21.45pt 0 0.05pt; text-indent: -0.05pt"><A HREF="ex991.htm">News Release: ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association Annual Meeting</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 21.45pt 0 0.05pt; text-indent: -0.05pt">&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: May 15,
    2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>





<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 15, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="essalogo.jpg" ALT="" STYLE="width: 177px; height: 76px"></P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Pharma Presents Therapeutic Potential
of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">HOUSTON&nbsp;and VANCOUVER, May 15, 2020 /CNW/
- ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for
the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual
American Urological Association (&quot;AUA&quot;) Annual &nbsp;Meeting.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In an oral poster presentation titled, &quot;The
preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor for the treatment of
prostate cancer&quot;, a more in-depth preclinical characterization of EPI-7386 including gene expression analyses and the toxicologic
profile was presented. The studies highlight new information about EPI-7386 including:</P>

<UL STYLE="list-style-type: disc">

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif"><B><I>In vitro</I>&nbsp;cellular gene expression analyses
demonstrate that EPI-7386:</B></LI>

<UL STYLE="list-style-type: circle">

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">Inhibits androgen-induced genes with major similarities
but some differences from enzalutamide in a cellular model sensitive to androgen receptor inhibitors.</LI>

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">In the same cellular model, the combination of enzalutamide
and EPI-7386 inhibits androgen-induced gene expression more completely and broadly.</LI>

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">EPI-7386 shows superiority to enzalutamide in inhibiting
androgen-induced genes in an androgen receptor resistant model, and in contrast to enzalutamide, also blocks genes induced by the
AR-V7 androgen receptor splice variant.</LI>

</UL>

</UL>

<UL STYLE="list-style-type: disc">

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif"><B>Toxicology studies evaluating the safety profile of
EPI-7386 demonstrate that: &nbsp;</B></LI>

<UL STYLE="list-style-type: circle">

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">Very high plasma exposures of EPI-7386 were achieved
across all studies.</LI>

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">The drug was well tolerated at both the low and middle
doses, corresponding to drug plasma exposures 2-5 fold higher than the efficacious exposures achieved in mouse xenograft models.</LI>

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif">The highest doses tested were characterized as the HNSTD
(highest non-severely toxic dose) and only exhibited body weight loss and reduced food consumption. The drug plasma exposures achieved
at this high dose were 7-10 fold higher than the efficacious exposures achieved in mouse xenograft models.</LI>

</UL>

</UL>

<UL STYLE="list-style-type: disc">

<LI STYLE="margin: 0pt 0 12pt; font-family: Arial, Helvetica, Sans-Serif"><B>The starting clinical dose of EPI-7386 will be 200
mg given once-daily </B></LI>

</UL>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;The breadth of <I>in vitro</I> and <I>in
vivo</I> studies utilized to profile EPI-7386 preclinically demonstrate an encouraging profile for EPI-7386 across a variety of
antiandrogen sensitive and antiandrogen-resistant cellular models, xenograft and patient-derived xenograft mouse models, and gene
expression analyses. The favorable toxicologic profile of EPI-7386 observed in our IND-enabling studies at very high exposures
will permit initiation of the Phase 1 study at a dose of 200 mg per day, which should allow us to reach biologically relevant blood
levels of EPI-7386 in patients quickly,&quot; said Dr. David R. Parkinson, President &amp; Chief Executive Officer.&nbsp; &quot;We
look forward to beginning patient dosing soon in our initial phase 1 study of EPI-7386 in mCRPC patients whose tumors are progressing
on current anti-androgens.&quot;.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.<BR>
</B>ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of
castration-resistant prostate cancer in patients whose disease is progressing despite treatment with current therapies. ESSA's
proprietary &quot;aniten&quot; compounds bind to the N-terminal domain of the androgen receptor (&quot;AR&quot;), inhibiting AR
driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with
current anti-androgens. The Company is currently conducting a phase 1 study of EPI-7386 in patients with metastatic castration-resistant
prostate cancer (&quot;mCRPC&quot;) who are failing current standard-of-care therapies. For more information, please visit www.essapharma.com&nbsp;and
follow us on Twitter under @ESSAPharma.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Prostate Cancer<BR>
</B>Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death
worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking
androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to
medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone
generally represents a transition to the lethal variant of the disease, mCRPC, and most patients ultimately succumb to the illness.
The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options
are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the meaning
of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, the timing and enrollment of a Phase 1 study
of EPI-7386,&nbsp;future presentations with respect to EPI-7386 and the content thereof, and other statements regarding EPI-7386,
including those surrounding the Company's clinical evaluation of EPI-7386.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited
to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary
regulatory approvals; and (iv) general business, market and economic conditions.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 19, 2019 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile.
Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made
and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances
should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against
attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content:http://www.prnewswire.com/news-releases/essa-pharma-presents-therapeutic-potential-of-epi-7386-at-2020-virtual-american-urological-association-aua-annual-meeting-301059903.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content: http://www.newswire.ca/en/releases/archive/May2020/15/c4242.html</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Company, Peter Virsik, Chief Operating
Officer, ESSA Pharma Inc., Contact: (778) 331-0962; Investor Relations, Alan Lada, Solebury Trout, Contact: (617) 221-8006, Email:
alada@soleburytrout.com</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 07:30e 15-MAY-20</P>



<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! 7P# 2(  A$! Q$!_\0
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M!2I>6TCA$N(F8] K@DT[,7,NY/1112&%%%% !1110 5X9\8?^1Q@_P"O%/\
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MG#.@][IGN87%+$+:S1-1117,=84444 %>-_&'7?/U"VT2,_);CSI?]\CY1^
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M "'-2_Z]Q_Z$*]3&?P)'DX+_ 'B)[/BC%%%?/'TP8HQ110 8I,"EHH ****
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M?VG'^7\3T/[*G_,CY>HKZA_X1_1_^@58_P#@.G^%'_"/Z/\ ] JQ_P# =/\
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M3XM3PC?W-R]FUR)HPFU9-N.<YZ&N7HKVYPC.+C+8\*G.5.2E'='KW_"ZH/\
MH"2_^! _^)H_X75!_P! 27_P('_Q->0T5S?4:';\3J_M#$?S?@CU[_A=4'_0
M$E_\"!_\31_PNJ#_ * DO_@0/_B:\AHH^HT.WXA_:&(_F_!'KW_"ZH/^@)+_
M .! _P#B:EMOC)#<W4, T613(ZIG[0.,G']VO'*M:7_R%K+_ *[I_P"A"E+
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
